Aiforia Technologies

31:45

Jukka Tapaninen, CEO, talks about medical software company Aiforia as an investment.

The share issue was expected, although it took place slightly earlier than we predicted, was smaller, and at a slightly lower valuation.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Welcome to follow Life Science Night on Tuesday, December 9 at 3:30 pm EET on inderesTV.

Aiforia's implemented cost savings will help manage its financing needs in the coming years while the turnaround of a strong customer base into accelerating revenue growth will take time.

The company intends to ensure the achievement of its mid-term strategic goals through adjustment measures, which, in our view, means turning the business profitable by 2027.

Aiforia will at least challenge and potentially replace its competitor IBEX's solutions in the customer relationship.

This is the first completed deployment of the framework agreement Aiforia announced last year. The release supports our current view that the transition of the company's key, already won, customer accounts to a clear volume phase would take place in 2026-2028, and thus does not cause pressure to change our forecasts.

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

Through the collaboration, Siemens Healthineers will begin offering Aiforia's AI-powered solutions as part of its digital pathology portfolio to its customers in Europe.